GeNeuro: Presentation at the International Society of NeuroVirology 2022 of Top-Line Data of Academic Collaborations Further Documenting the Long-Term Expression of the Proinflammatory and Neuropathogenic W-ENV Protein in Cohorts of Post-COVID...
17 Ottobre 2022 - 7:30AM
Business Wire
- Presentation at the 18th meeting of the International
Society of NeuroVirology showing for the first time top-line
results of collaborative efforts ran in the context of COVID-19
with institutions such as NINDS and NWU.
- New data reinforce evidence that SARS-coV-2 triggers
expression of the pathogenic W-ENV protein. In addition to the
already presented data showing expression on the endothelial cells
of the brain, heart and lung, the NINDS data presented at the
meeting also showed expression of W-ENV in brain microglia of
patients who died with COVID-19.
- The new data developed with Northwestern University showed
that W-ENV may be detected in the serum of patients affected by
post-COVID syndromes for up to two years after the
infection.
- While patients who had a severe acute phase appear to be
more likely to continue expressing W-ENV, there were also about 20%
of post-COVID patients who had a mild acute phase found positive to
W-ENV.
Regulatory News:
Presentation at the International Society of
NeuroVirology 2022 of Top-Line Data of Academic Collaborations
Further Documenting the Long-Term Expression of the Proinflammatory
and Neuropathogenic W-ENV Protein in Cohorts of Post-COVID
Patients
GeNeuro (Euronext Paris: CH0308403085 - GNRO), a
biopharmaceutical company focused on stopping causal factors
driving the progression of neurodegenerative and autoimmune
diseases such as multiple sclerosis (MS), amyotrophic lateral
sclerosis (ALS) and Post-Acute Sequelae of COVID-19 (PASC,
long-COVID or post-COVID), announced today that its Chief
Scientific Officer, Dr. Hervé Perron, unveiled new data further
documenting the presence of W-ENV in cohorts of post-COVID patients
at the 18th Symposium of the International Society of Neuro
Virology (ISNV) held on October 11-14, 2022.
Specifically, these new results reinforce the evidence that
SARS-CoV-2 triggers the expression of the pathogenic W-ENV protein.
In addition to the already presented data showing expression on the
endothelial cells of the brain, heart and lung, the National
Institute of Neurological Disorders and Stroke (NINDS) data
presented at the meeting also showed expression of W-ENV in brain
microglia of patients who died with COVID-19.
The expression of W-ENV was already well documented during the
acute phase of the disease in hospitalized patients. The data
developed together with Northwestern University (NWU) showed that
W‑ENV may be detected in the serum of patients affected by
post-COVID syndromes, for up to two years after the infection.
While patients who had a severe acute phase appear to be more
likely to continue expressing W-ENV, there were about 20% of
post-COVID patients who had a mild acute phase found positive to
W-ENV.
“Whilst the role of common viruses from the Herpes virus family,
in particular the Epstein-Barr virus, in activating pathogenic
proteins from the HERV-W family is already well documented, several
academic groups have now shown that SARS-CoV-2 is also a potent
activator of HERV-W” said Dr. Hervé Perron, CSO of GeNeuro.
“This is of particular interest in the light of the emergence of
post-COVID as a major public-health concern worldwide. In the last
two years, we have initiated research partnerships with prestigious
academic groups that have allowed us to confirm the long-term
expression of the proinflammatory and neuropathogenic W-ENV protein
in cohorts of post-COVID patients.”
The detailed results of these collaborations have been and are
being submitted to peer-review journals and will be available in
the coming months.
Expression of the pathogenic W-ENV protein triggered by the
SARS-CoV-2 infection, continuing long after the acute phase has
been resolved, is suspected to have a major role in the severe
neurological and psychiatric long-term syndromes affecting many
post-COVID patients. GeNeuro has recently initiated a clinical
trial evaluating temelimab, its highly specific anti-W-ENV
antibody, as a Disease Modifying Therapy in post-COVID patients
suffering from severe neurological and psychiatric symptoms and who
are positive for the presence of the pathogenic W-ENV protein in
their blood. This represents the first personalized medicine
clinical trial against long-COVID.
About GeNeuro
GeNeuro‘s mission is to develop safe and effective treatments
against neurological disorders and autoimmune diseases, such as
multiple sclerosis, by neutralizing causal factors encoded by human
endogenous retroviruses (HERVs), which represent 8% of human
DNA.
GeNeuro is based in Geneva, Switzerland and has R&D
facilities in Lyon, France. It has rights to 17 patent families
protecting its technology.
For more information, visit: www.geneuro.com
Disclaimer
This press release contains certain forward - looking statements
and estimates concerning GeNeuro’s financial condition, operating
results, strategy, projects and future performance and the markets
in which it operates. Such forward-looking statements and estimates
may be identified by words, such as “anticipate,” “believe,” “can,”
“could,” “estimate,” “expect,” “intend,” “is designed to,” “may,”
“might,” “plan,” “potential,” “predict,” “objective,” “should,” or
the negative of these and similar expressions. They incorporate all
topics that are not historical facts. Forward looking statements,
forecasts and estimates are based on management’s current
assumptions and assessment of risks, uncertainties and other
factors, known and unknown, which were deemed to be reasonable at
the time they were made but which may turn out to be incorrect.
Events and outcomes are difficult to predict and depend on factors
beyond the company’s control. Consequently, the actual results,
financial condition, performances and/or achievements of GeNeuro or
of the industry may turn out to differ materially from the future
results, performances or achievements expressed or implied by these
statements, forecasts and estimates. Owing to these uncertainties,
no representation is made as to the correctness or fairness of
these forward-looking statements, forecasts and estimates.
Furthermore, forward-looking statements, forecasts and estimates
speak only as of the date on which they are made, and GeNeuro
undertakes no obligation to update or revise any of them, whether
as a result of new information, future events or otherwise, except
as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221016005037/en/
GeNeuro Jesús Martin-Garcia Chairman and CEO +41 22 552
4800 investors@geneuro.com
NewCap (France) Mathilde Bohin/Louis-Victor Delouvrier
(investors) +33 1 44 71 98 52
Arthur Rouillé (media) +33 1 44 71 94 98 geneuro@newcap.eu
RooneyPartners (US) Jeanene Timberlake (media) +1 646 770
8858 jtimberlake@rooneypartners.com
Grafico Azioni GeNeuro (EU:GNRO)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni GeNeuro (EU:GNRO)
Storico
Da Apr 2023 a Apr 2024